| Literature DB >> 34288218 |
Juliana Pedro1, Sara Monteiro-Reis2,3, Carina Carvalho-Maia2,3, Rui Henrique2,3,4, Carmen Jerónimo2,3,4, Eunice R Silva1.
Abstract
OBJECTIVE: A large number of studies have been conducted exploring the effects of mindfulness programs on health outcomes, such as psychological and biological outcomes. However, there is substantial heterogeneity among studies and, consequently, in the systematic reviews/meta-analyses. Since clinical practice is massively informed by evidence on review studies, our main objective was to summarize the reported evidence regarding the effects of structured mindfulness-based programs on psychological, biological, and quality-of-life outcomes in cancer patients.Entities:
Keywords: MBCT; MBSR; anxiety; cancer; immune response; inflammatory-related markers; meta-review; mindfulness; oncology; psychological
Mesh:
Year: 2021 PMID: 34288218 PMCID: PMC9290489 DOI: 10.1002/pon.5771
Source DB: PubMed Journal: Psychooncology ISSN: 1057-9249 Impact factor: 3.955
FIGURE 1Study flow chart (Moher et al. )
Characteristics of included studies (n = 10)
| Author (year, country) | Design | Databases searched | Goal (inclusion and exclusion criteria | Search period | Sample characteristics | Interventions addressed | Control group | Outcome measure (primary) | No. studies included in the original | No. studies meeting criteria | Range follow‐up times |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Calero (2018, Spain) | SR | PubMed, CINAHL, and PsycINFO | RCTs with follow‐up | January 2011 to October 2017 | 1839 women survivors of BC stage 0–III (including those in hormonal therapy) | MBCT/MBSR/MBCR | UC | Psychological | 10 | 9 | 3 months to 6–12 months after |
| Exclusion criteria: chemotherapy/radiotherapy | Age range: 18–75; mean = 55 years | ||||||||||
| Cillessen (2019, Denmak) | SR & M | PubMed, Web of Science, PsycINFO, and CINAHL | RCTs | Inception to 10 October 2018 | 3274 cancer patients and survivors (any cancer location, all stages) | MBCT/MBSR/MBCR | WL | Stress, anxiety, depression | 29 RCTs (38 papers) | 23 | Mean follow‐up: 6 months |
| Age range: 46–71; mean = 55 years | |||||||||||
| Cramer (2012, Germany) | SR & M | MEDLINE, Cochrane Library, Embase, CAMbase, and PsycINFO | RCTs and BC patients | Inception to November 2011 | 327 BC patients (including both in chemotherapy/radiation) | MBSR/MBCT | UC, AC, no treatment | QoL, psychological health | 3 | 3 | 12–24 months |
| Exclusion criteria: metastatic cancer | Age range: 50–57.5 years | ||||||||||
| Ford (2020, United States) | M | PsycINFO, MEDLINE | RCTs | Inception to December 2017 | 369 men with cancer (prostate, mixed, lung) | MBSR/MBCT | UC, WL, AC | Psychosocial outcomes | 17 | 9 | 2–12 months |
| Men with cancer of any treatment status (including pretreatment, current treatment, and posttreatment) | 369 men (in the nine studies using MBSR, MBCT) | ||||||||||
| At least 10% of the study population was male | |||||||||||
| Haller (2017, Germany) | SR & M | PubMed (including MEDLINE), Scopus (including Embase), and Cochrane CENTRAL | RCTs, cluster RCTs, randomized cross over | Inception to October 2016 | 1709 BC participants (stage 0–IV); the majority not metastatic | MBCT/MBSR | UC, AC | QoL (primary), fatigue, stress, anxiety, depression | 14 (10 samples) | 10 | 3–12 months |
| MBCT/MBSR (ACT excluded, mindfulness body exercise) | Mean age = 54.3 years old | ||||||||||
| Includes both participants who had completed cancer treatments and who were undergoing adjuvant treatment | |||||||||||
| Piet (2012, Denmark) | SR & M | Embase, PubMed, PsycINFO, Web of Science, Scopus, and the Cochrane CENTRAL | Inception to 5 March 2012 | 1403 cancer patients and survivors, BC (77%), prostate cancer, mixed cancer | MBSR/MBCT | UC, WL | Anxiety, depression, mindfulness skills | 22 | 9 RCTs on meta‐analysis ( | 1–12 months; mean post‐test follow‐up: 6.6 months | |
| Mean age = 55 years old | |||||||||||
| Schell (2019, Germany) | SR | Cochrane CENTRAL, MEDLINE, Embase, WHO ICTRP, and ClinicalTrials.gov | RCTs | January 2005–2017 | 1957 women with BC | Only MBSR | UC | QoL | 10 | 10 | 6 months to 2 years |
| All stages of BC, including metastatic cancer | Age range: 56–59 years old | ||||||||||
| Includes both participants who had completed cancer treatments and who were undergoing adjuvant treatment | |||||||||||
| Xunlin (2020, Singapore) | SR & M | PubMed, Embase, Cochrane Library, Scopus, CINAHL, PyscINFO, MEDLINE, ScienceDirect, and Clinical Trials Registry | RCTs | 2008–2018 | 3476 cancer patients and survivors | MBSR/MBCT/MBCR | UC, WL, AC | Psychological and QoL | 29 | 24 on meta‐analysis addressing MBSR/MBCT/MBCR | Not reported |
| Cancer patients or survivors aged ≥18 years old | Age range: 38.8–70.7 years old | ||||||||||
| Any type and stage of cancer, and treatment status | BC, prostate, colorectal, lung cancer, mixed cancer | ||||||||||
| Zhang (June 2016, China) | SR & M | PubMed, Cochrane Library, EBSCO, Chinese Biomedical Literature Database, and Chinese Digital Journals Full‐text | RCTs | Inception to January 2015 | 951 BC patients; cancer stage 0–II | MBSR | UC, WL | Physical health, psychological health, and QoL | 7 | 7 | Not reported |
| Diagnosis of BC regardless treatment status | |||||||||||
| Zhang, Qiuxiang (2019, China) | SR & M | Cochrane Library, Cochrane CENTRAL, PsycINFO, Web of science, MEDLINE, Embase, CNKI, and CBM | Trails on MBSR versus control group | February to May 2018 | 1505 BC patients; a majority of non‐metastatic cancer | MBSR | UC, AC, no treatment | Symptom, QoL | 14 | 14 | 4 weeks to 24 months |
| Mean age = 48.17 years old (range 40.67–56.90) |
Abbreviations: AC, active control group; BC, breast cancer; M, meta‐analysis; MBCR, Mindfulness‐Based Cancer Recovery; MBCT, Mindfulness‐Based Cognitive Therapy; MBSR, Mindfulness‐Based Stress Reduction; QoL, quality of life; RCT, randomized controlled trial; SR, systematic review; UC, usual care; WL, waist‐list control group.